The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease

Vascular Medicine

Volumn 9, Issue 4, 2004, Pages 271-277

  Hiatt, William R ^a   Klepack, Ellen ^b   Nehler, Mark ^a   Regensteiner, Judith G ^a   Blue, John ^b   Imus, James ^b   Criqui, Michael H ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cholesterol; Clinical trials; Exercise performance; Intermittent claudication; Peripheral arterial disease

Indexed keywords

APOLIPOPROTEIN B; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANKLE BRACHIAL INDEX; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HEALTH CARE FACILITY; HUMAN; HYPERTENSION; INFECTION; INJURY; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THORAX PAIN; TIME; TREADMILL EXERCISE; UNITED STATES; WALKING;

ACETATES; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PSYCHOMOTOR PERFORMANCE; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 13444280370     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm569oa     Document Type: Article

References (21)

1. Golomb BA, Criqui MH, Bundens WP. Epidemiology. In: Creager MA (ed). Management of peripheral arterial disease. Medical, surgical, and interventional aspects. London: Remedica Publishing Limited, 2000: 1-18.
2. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 1998; 3: 241-45.
3. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
5. Heinonen TM. Inhibition of acyl coenzyme A-cholesterol acyltranferase: a possible treatment of atherosclerosis? Curr Atheroscler Rep 2002; 4: 65-70.
6. Cases S, Novak S, Yao-Wu Z et al. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. J Biol Chem 1998; 273: 26 755-64.
7. Burnett JR, Wilcox LJ, Huff MW. Acyl-coenzyme A:cholesterol acyltransferase and hepatic apolipoprotein B secretion. Clin Chim Acta 1999; 286: 231-42.
8. Kinnunen PM, DeMichele A, Lange LG. Chemical modification of acyl-CoA:cholesterol O-acyltransferase. 1. Identification of acyl-CoA:O-cholesterol O-acyltransferase subtypes by differential diethyl pyrocarbonate sensitivity. Biochemistry 1988; 27: 7344-50.
9. Delsing DJM, Offerman EH, van der Boom H et al. The acyl-CoA:cholesterol acyltransferase (ACAT)-inhibitor avasimibe reduces atherosclerosis independently of its lipid-lowering effect in cholesterol-fed apoE3-Leiden transgenic mice. Circulation 1999; 100: I613 (abstract).
10. Bocan TMA, Krause BR, Rosebury WS et al. The ACAT inhibitor, avasimibe, reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 70-79.
11. Niclosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011, is effective in prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998; 137: 77-85.
12. Vora J, Stern R, Lathia, C. Clinical pharmacokinetics of CI-1011 an ACAT inhibitor. Pharm Res 1997; 14: S505.
13. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
14. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients voth peripheral arterial disease. J Vasc Med Biol 1990; 2: 142-52.
15. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control National Heart, Lung, and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9: 105-35.
16. Steiner PM, Freidel J, Breminer WF, Stein E. Standardization of micro-methods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinic's methodology. J Clin Chem Clin Biochem 1981; 19: 850 (abstract).
17. Steel BW, Koehler DF, Azar MM, Blaszkowski TP, Kuba K, Demsey ME. Enzymatic determinations of cholesterol from high-density-lipoprotein fractions were prepared by a precipitation technique. Clin Chem 1976; 22: 98-101.
18. Albers JJ, Marcovina SM. Apolipoprotein measurements. In: Kreisber RA, Segrest JA (eds). Plasma lipoproteins and coronary artery disease. Boston: Blackwell Scientific Publications, 1992: 265-88.
19. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-802.
20. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
21. Labs K-H, Dormandy JA, Jaeger KA, Stuerzebecher C-S, Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 1999; 100: e75-81.